Appropriatezza diagnostico-terapeutica in oncologia - Quaderni del ...
Appropriatezza diagnostico-terapeutica in oncologia - Quaderni del ... Appropriatezza diagnostico-terapeutica in oncologia - Quaderni del ...
Ministero della Salute Hanks GE, Pajak TF, Porter A, et al.; Radiation Therapy Oncology Group. RTOG 92-02: Phase III trial long term adjuvant androgen deprivation after neoadsuperare il 3%. Per la verifica degli altri parametri di qualità del trattamento radioterapico si rimanda al già citato rapporto ISTISAN 04-34 sull’“Indicazione per l’assicurazione di qualità nella radioterapia conformazionale”. La qualità del trattamento oncologico può essere valutata tramite differenti parametri, essendo il trattamento stesso per sua natura vario e complesso, e difficilmente inquadrabile in un’unica tipologia di prestazione come avviene per quello chirurgico e radiante. Poiché ancora oggi i due terzi dei pazienti affetti da neoplasia prostatica hanno un’età superiore ai 65 anni, è indice di qualità l’adozione sistematica di protocolli di Valutazione Geriatrica Multidimensionale (VGM) per i pazienti di età superiore ai 70 anni. Al di là della qualità percepita dal paziente, solo parzialmente desumibile attraverso appositi questionari di valutazione, che comunque devono costituire un aiuto prezioso nella certificazione della qualità del Centro, e tralasciando la già citata necessità di preparazione e qualifica del personale anche di tipo infermieristico deputato alla gestione di questi pazienti, giova qui ricordare soltanto uno dei differenti indicatori di qualità, quale quello delle liste di attesa nella tempistica delle prestazioni erogate: queste dovrebbero essere tali da non superare i 10 giorni lavorativi per una prima visita ambulatoriale, i 15 giorni per l’attivazione di un trattamento in regime di day hospital, i 15 giorni per l’accesso in reparto, in caso di ricovero ordinario. La struttura deve poter dimostrare un’attività scientifica di pubblicazioni sul cancro della prostata certificata su riviste peer reviewed. In questo caso l’accreditamento deve essere previsto su un arco di tempo tri- o quinquennale utilizzando i criteri di normalizzazione dell’IF (impact factor) adottati dal Ministero della Salute per l’Accreditamento degli IRCCS. Bibliografia Albertsen PC, Hanley JA, Gleason DF, Barry MJ. Compet ing risk analysis of men aged 55 to 74 years at the diagnosis managed conservatively for clinically localized prostate cancer. JAMA 1998; 280: 975-80 Anderson J. The role of antiandrogen monotherapy in the treatment of prostate cancer. BJU Int 2003; 91: 455-61 Aus G, Abbou CC, Bolla M, et al. EAU (European Association of Urology) Guidelines on Prostate Cancer, 2006 Barry MJ, Albertsen PC, Bagshaw MA, et al. Outcomes for men with clinically non metastatic prostate carcinoma managed with radical prostatectomy, external beam radiotherapy, or expectant management: a retrospective analysis. Cancer 2001; 91: 2302-14 Blasko JC, Grimm PD, Sylsvester JE, Cavanaugh W. The role of external beam radiotherapy with I-125/Pd- 103 brachytherapy for prostate carcinoma. Radiother Oncol 2000; 57: 273-8 Bolla M, Collette L, Blank L, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 2002; 360: 103-6 Bolla M, van Poppel H, Collette L, et al.; European Organization for Research and Treatment of Cancer. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet 2005; 366: 572-8 Byar DP, Corle DK. Hormone therapy for prostate cancer: results of the Veterans Administration Cooperative Urological Research Group studies. NCI Monogr 1998: 165-70 Calais Da Silva FM, Calais Da Silva F, Bono A, et al. South European Uroncological Group Phase III intermittent MAB vs continuous MAB. ASCO Annual Meeting Proceedings 2006; 24 (18S): 4513 68
Neoplasie della prostata 4 juvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate. J Clin Oncol 2003; 21: 3972-8 Hricak H, Choyke PL, Eberhardt SC, et al. Imaging prostate cancer: a multidisciplinary perspective. Radiology 2007; 243: 28-53 Linee Guida AIOM (Associazione Italiana Oncologia Medica) sul Carcinoma della Prostata, 2007 Linee Guida AURO (Associazione Urologi Italiani) su: Carcinoma prostatico: diagnosi stadiazione e terapia, 2008 Lu-Yao GL, Yao SL. Population-based study of long term survival in patients with clinically localized prostate cancer. Lancet 1997; 349: 906-10 McLeod DG, Iversen P, See WA, et al.; Casodex Early Prostate Cancer Trialists’ Group. Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer. BJU Int 2006; 97: 247-54 Messing EM, Manola J, Yao J, et al.; Eastern Cooperative Oncology Group study EST 3886. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol 2006; 76: 472-9 NCCN (National Comprehensive Cancer Network) practice guidelines in Oncology, Prostate Cancer, 2009 Partin AW, Mangold LA, Lamm DM, et al. Contemporary update of the prostate cancer staging nomograms (Partin tables) for the new millennium. Urology 2001; 58: 843-8 Peeters ST, Heemsbergen WD, Koper PC, et al. Dose-response in radiotherapy for localized prostate cancer: results of the Dutch Multicenter randomized Phase III Trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol 2006; 13: 1990-9 Petrylak D, Tangen M, Hussain MH, et al. SWOG 99-16: Docetaxel and extramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351: 1513-20 Pilepich MV, Winter K, Lawton CA, et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma-long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys 2005; 61: 1285-90 Prostate Cancer Trialists’ Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of the randomized trials. Lancet 2000; 355: 1491-8 Roach M 3rd, DeSilvio M, Lawton C et al.; Radiation Therapy Oncology Group 9413. Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413. J Clin Oncol 2003; 21: 1904-11 Roach M 3rd, Hanks G, Thames H Jr, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendation of the RTOG- ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 2006; 65: 965-74 Stanford JL, Feng Z, Hamilton AS, et al. Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer: the Prostate Cancer Outcomes Study. JAMA 2000; 283: 354-60 Tannock IF, de Wit R, Berry WR, et al.; TAX 327 Investigators. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 1502-12 Taylor CD, Elson P, Trump DL. Importance of continued testicular suppression in hormone-refractory prostate cancer. J Clin Oncol 1993; 11: 2167-72 The Medical Research Council Prostate Cancer Working Party Investigators Group. Immediate versus deferred treatment for advanced prostatic cancer: initial results of the MRC trial. Br J Urol 1997; 79: 235-46 Thompson IM Jr, Tangen CM, Paradelo J, et al. Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. JAMA 2006; 296: 2329-35 Zelefsky M, D’Amico A. External beam radiotherapy for locally, advanced and recurrent prostate cancer. Course 402, 44 th Annual Meeting ASTRO, 2002 69
- Page 34 and 35: Ministero della Salute 2.6. Carcino
- Page 36 and 37: Ministero della Salute Per consegui
- Page 38 and 39: Ministero della Salute ESMO minimum
- Page 40 and 41: Ministero della Salute (segue) Situ
- Page 42 and 43: Ministero della Salute • T1: tumo
- Page 44 and 45: Ministero della Salute in situ (flu
- Page 46 and 47: Ministero della Salute estesi oltre
- Page 48 and 49: Ministero della Salute adeguato per
- Page 50 and 51: Ministero della Salute quelle in po
- Page 52 and 53: Ministero della Salute premenopausa
- Page 54 and 55: Ministero della Salute bicina e doc
- Page 56 and 57: Ministero della Salute zolo è supe
- Page 58 and 59: Ministero della Salute • Anestesi
- Page 60 and 61: Ministero della Salute Buzdar AU, V
- Page 62 and 63: Ministero della Salute Appendice: D
- Page 65 and 66: n. 3, maggio-giugno 2010 Ministero
- Page 67 and 68: Neoplasie della prostata 4 metodo v
- Page 69 and 70: Neoplasie della prostata 4 asse cor
- Page 71 and 72: Neoplasie della prostata 4 Metastas
- Page 73 and 74: Neoplasie della prostata 4 l’appr
- Page 75 and 76: Neoplasie della prostata 4 Recidiva
- Page 77 and 78: Neoplasie della prostata 4 tensione
- Page 79 and 80: Neoplasie della prostata 4 thdrawal
- Page 81 and 82: Neoplasie della prostata 4 PSA dopo
- Page 83: Neoplasie della prostata 4 tazione
- Page 87 and 88: Neoplasie della prostata 4 (segue)
- Page 89 and 90: Neoplasie della prostata 4 (segue)
- Page 91: Neoplasie della prostata 4 (segue)
- Page 94 and 95: Ministero della Salute organizzativ
- Page 96 and 97: Ministero della Salute Cancer (UICC
- Page 98 and 99: Ministero della Salute Mucosa Lamin
- Page 100 and 101: Ministero della Salute Hereditary n
- Page 102 and 103: Ministero della Salute 5.5. Trattam
- Page 104 and 105: Ministero della Salute e molecolari
- Page 106 and 107: Ministero della Salute anticorpi an
- Page 108 and 109: Ministero della Salute Un programma
- Page 110 and 111: Ministero della Salute pali societ
- Page 112 and 113: Ministero della Salute necessitare
- Page 114 and 115: Ministero della Salute Appendice: D
- Page 116 and 117: Ministero della Salute Esami di fol
- Page 118 and 119: Ministero della Salute resecabilit
- Page 120 and 121: Ministero della Salute endocrini po
- Page 122 and 123: Ministero della Salute • i segni
- Page 124 and 125: Ministero della Salute nificato sul
- Page 126 and 127: Ministero della Salute vivenza), no
- Page 128 and 129: Ministero della Salute 6.9. Terapie
- Page 130 and 131: Ministero della Salute neoplastica,
- Page 132 and 133: Ministero della Salute 1,8-2,0 Gy).
Neoplasie <strong>del</strong>la prostata 4<br />
juvant hormonal cytoreduction and radiotherapy <strong>in</strong><br />
locally advanced carc<strong>in</strong>oma of the prostate. J Cl<strong>in</strong> Oncol<br />
2003; 21: 3972-8<br />
Hricak H, Choyke PL, Eberhardt SC, et al. Imag<strong>in</strong>g<br />
prostate cancer: a multidiscipl<strong>in</strong>ary perspective. Radiology<br />
2007; 243: 28-53<br />
L<strong>in</strong>ee Guida AIOM (Associazione Italiana Oncologia<br />
Medica) sul Carc<strong>in</strong>oma <strong>del</strong>la Prostata, 2007<br />
L<strong>in</strong>ee Guida AURO (Associazione Urologi Italiani) su:<br />
Carc<strong>in</strong>oma prostatico: diagnosi stadiazione e terapia, 2008<br />
Lu-Yao GL, Yao SL. Population-based study of long<br />
term survival <strong>in</strong> patients with cl<strong>in</strong>ically localized prostate<br />
cancer. Lancet 1997; 349: 906-10<br />
McLeod DG, Iversen P, See WA, et al.; Casodex Early<br />
Prostate Cancer Trialists’ Group. Bicalutamide 150<br />
mg plus standard care vs standard care alone for early<br />
prostate cancer. BJU Int 2006; 97: 247-54<br />
Mess<strong>in</strong>g EM, Manola J, Yao J, et al.; Eastern Cooperative<br />
Oncology Group study EST 3886. Immediate<br />
versus deferred androgen deprivation treatment <strong>in</strong> patients<br />
with node-positive prostate cancer after radical<br />
prostatectomy and pelvic lymphadenectomy. Lancet<br />
Oncol 2006; 76: 472-9<br />
NCCN (National Comprehensive Cancer Network)<br />
practice gui<strong>del</strong><strong>in</strong>es <strong>in</strong> Oncology, Prostate Cancer, 2009<br />
Part<strong>in</strong> AW, Mangold LA, Lamm DM, et al. Contemporary<br />
update of the prostate cancer stag<strong>in</strong>g nomograms<br />
(Part<strong>in</strong> tables) for the new millennium. Urology<br />
2001; 58: 843-8<br />
Peeters ST, Heemsbergen WD, Koper PC, et al. Dose-response<br />
<strong>in</strong> radiotherapy for localized prostate cancer: results<br />
of the Dutch Multicenter randomized Phase III Trial compar<strong>in</strong>g<br />
68 Gy of radiotherapy with 78 Gy. J Cl<strong>in</strong> Oncol<br />
2006; 13: 1990-9<br />
Petrylak D, Tangen M, Hussa<strong>in</strong> MH, et al. SWOG<br />
99-16: Docetaxel and extramust<strong>in</strong>e compared with<br />
mitoxantrone and prednisone for advanced refractory<br />
prostate cancer. N Engl J Med 2004; 351: 1513-20<br />
Pilepich MV, W<strong>in</strong>ter K, Lawton CA, et al. Androgen<br />
suppression adjuvant to def<strong>in</strong>itive radiotherapy <strong>in</strong> prostate<br />
carc<strong>in</strong>oma-long-term results of phase III RTOG<br />
85-31. Int J Radiat Oncol Biol Phys 2005; 61: 1285-90<br />
Prostate Cancer Trialists’ Collaborative Group. Maximum<br />
androgen blockade <strong>in</strong> advanced prostate cancer: an overview<br />
of the randomized trials. Lancet 2000; 355: 1491-8<br />
Roach M 3rd, DeSilvio M, Lawton C et al.; Radiation<br />
Therapy Oncology Group 9413. Phase III trial compar<strong>in</strong>g<br />
whole-pelvic versus prostate-only radiotherapy<br />
and neoadjuvant versus adjuvant comb<strong>in</strong>ed androgen<br />
suppression: Radiation Therapy Oncology Group<br />
9413. J Cl<strong>in</strong> Oncol 2003; 21: 1904-11<br />
Roach M 3rd, Hanks G, Thames H Jr, et al. Def<strong>in</strong><strong>in</strong>g<br />
biochemical failure follow<strong>in</strong>g radiotherapy with or without<br />
hormonal therapy <strong>in</strong> men with cl<strong>in</strong>ically localized<br />
prostate cancer: recommendation of the RTOG-<br />
ASTRO Phoenix Consensus Conference. Int J Radiat<br />
Oncol Biol Phys 2006; 65: 965-74<br />
Stanford JL, Feng Z, Hamilton AS, et al. Ur<strong>in</strong>ary and<br />
sexual function after radical prostatectomy for cl<strong>in</strong>ically<br />
localized prostate cancer: the Prostate Cancer Outcomes<br />
Study. JAMA 2000; 283: 354-60<br />
Tannock IF, de Wit R, Berry WR, et al.; TAX 327 Investigators.<br />
Docetaxel plus prednisone or mitoxantrone<br />
plus prednisone for advanced prostate cancer. N Engl<br />
J Med 2004; 351: 1502-12<br />
Taylor CD, Elson P, Trump DL. Importance of cont<strong>in</strong>ued<br />
testicular suppression <strong>in</strong> hormone-refractory prostate<br />
cancer. J Cl<strong>in</strong> Oncol 1993; 11: 2167-72<br />
The Medical Research Council Prostate Cancer Work<strong>in</strong>g<br />
Party Investigators Group. Immediate versus deferred<br />
treatment for advanced prostatic cancer: <strong>in</strong>itial<br />
results of the MRC trial. Br J Urol 1997; 79: 235-46<br />
Thompson IM Jr, Tangen CM, Para<strong>del</strong>o J, et al. Adjuvant<br />
radiotherapy for pathologically advanced prostate<br />
cancer: a randomized cl<strong>in</strong>ical trial. JAMA 2006;<br />
296: 2329-35<br />
Zelefsky M, D’Amico A. External beam radiotherapy<br />
for locally, advanced and recurrent prostate cancer.<br />
Course 402, 44 th Annual Meet<strong>in</strong>g ASTRO, 2002<br />
69
Change language